|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Neurology (W.T., G.H., D.J.B., P.F.C.) and Institute of Human Genetics (P.F.C.), The University of Newcastle upon Tyne, UK; Unit of Molecular Neurogenetics (D.G., G.F., M.Z.), Pierfranco and Luisa Mariani Center for the Study of Children’s Mitochondrial Disorders, National Neurological Institute, Milan, Italy; and Department of Neurology (D.J.B., P.F.C.), Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, UK.
* To whom correspondence should be addressed. E-mail: p.f.chinnery{at}ncl.ac.uk.
Abstract-- We studied POLG1 in 140 UK patients with idiopathic Parkinson disease (PD) and 279 Italian patients with PD and compared them to a UK control group (n = 207) and an Italian control group (n = 285). Our observations do not support a role for common POLG1 genetic variants in PD and indicate that dominant POLG1 mutations are a rare cause of parkinsonism in the general population.
This article has been cited by other articles:
![]() |
M. A. Graziewicz, R. J. Bienstock, and W. C. Copeland The DNA polymerase {gamma} Y955C disease variant associated with PEO and parkinsonism mediates the incorporation and translesion synthesis opposite 7,8-dihydro-8-oxo-2'-deoxyguanosine Hum. Mol. Genet., November 15, 2007; 16(22): 2729 - 2739. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |